Placebo of HM15275

DRUG3 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

ObeseObesityT2DMType 2 Diabetes Mellitus

Phase 1

A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.

CompletedNCT06481098

Hanmi Pharmaceutical Company LimitedObesity

Start: 2024-05-28End: 2025-05-02Updated: 2025-05-22

Phase 2

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

Active, not recruitingNCT07205900

Hanmi Pharmaceutical Company LimitedObese, Obesity

Start: 2025-12-02End: 2027-01-01Updated: 2026-04-08

Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus

RecruitingNCT07527650

Hanmi Pharmaceutical Company LimitedT2DM, Type 2 Diabetes Mellitus

Start: 2026-05-18End: 2027-10-01Target: 180Updated: 2026-08-17